October 8, 2018 09:41 AM EDT

Reorganization of OND to support new drug review modernization, Woodcock says

Zachary Brennan

Senior Editor

The reorganization of the FDA’s Office of New Drugs will help support the modernization of new drug reviews, Janet Woodcock, head of the FDA’s Center …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reorganization of OND to support new drug review modernization, Woodcock says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Re­or­ga­ni­za­tion of OND to sup­port new drug re­view mod­ern­iza­tion, Wood­cock says

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Reorganization of OND to support new drug review modernization, Woodcock says